This is an interesting trial. The company has a nuclear medicine including radium isotopes. These atoms decay such that a large amount of energy is released in a very small area, perfect for those with bone metastases. The material is bone and tumor seeking. Earlier nuclear compounds included Samarium which releases smaller energy packets over a much larger distance. Strontium was used even longer ago with the same limitations as Samarium. One wishes the damage to be contained to the nearest possible area within the tumor and maintaining marrow function and other bone health. Those with substantial physics background, chime in.
The Phase II trial showed significant improvement in symptoms and also survival. That is a great combination. The Norwegian company taking this treatment to trial has just agreed with Bayer, the German giant firm for rights to this treatment. This is a good sign.
Here is the video which explains the trial and drug mechanism. It is at Tulane Hospital and nowhere else in the US at this time. There is a placebo arm.